740
Views
3
CrossRef citations to date
0
Altmetric
Commentary

How to fight SARS-COV-2 vaccine hesitancy in patients suffering from chronic and immune-mediated skin disease: four general rules

ORCID Icon, , , , , , & show all
Pages 4105-4107 | Received 21 Jul 2021, Accepted 05 Aug 2021, Published online: 01 Oct 2021

References

  • Yadav S, Yadav PK. Basic reproduction rate and case fatality rate of COVID-19: application of meta-analysis. medRxiv. 2020. doi:10.1101/2020.05.13.20100750.
  • Neumman-Bohme S, Varghese NE, Sabat I, Barros PP, Brouwer W, van Exel J, Schreyögg J, Stargardt T. Once we have it, will we use it? A European survey on willingness to be vaccinated against COVID-19. Eur J Health Econ. 2020;21:977–82. doi:10.1007/s10198-020-01208-6. PMID: 32591957.
  • Campanati A, Brisigotti V, Diotallevi F, D’Agostino GM, Paolinelli M, Radi G, Rizzetto G, Sapigni C, Tagliati C, Offidani A. Active implications for dermatologists in ‘SARS-CoV-2 ERA’: personal experience and review of literature. J Eur Acad Dermatol Venereol. 2020 Aug;34(8):1626–32. doi:10.1111/jdv.16646. PMID: 32426855.
  • Radi G, Diotallevi F, Campanati A, Offidani A. Global coronavirus pandemic (2019-nCOV): implication for an Italian medium size dermatological clinic of a II level hospital. J Eur Acad Dermatol Venereol. 2020 May;34(5):e213–e214. doi:10.1111/jdv.16386.
  • Diotallevi F, Campanati A, Bianchelli T, Bobyr I, Luchetti MM, Marconi B, Martina E, Radi G, Offidani A. Skin involvement in SARS-CoV-2 infection: case series. J Med Virol. 2020;92(11):2332–34. doi:10.1002/jmv.26012. Epub 2020 Jun 2
  • Radi G, Campanati A, Diotallevi F, Bianchelli T, Offidani A. Novel therapeutic approaches and targets for treatment of psoriasis. Curr Pharm Biotechnol. 2021;22(1):7–31. doi:10.2174/1389201021666200629150231. PMID: 32598253
  • Ghazawi FM, Lim M, Dutz JP, Kirchhof MG. Infection risk of dermatologic therapeutics during the COVID-19 pandemic: an evidence-based recalibration. Int J Dermatol. 2020 Sep;59(9):1043–56. doi:10.1111/ijd.15028. Epub 2020 Jul 3. PMID: 32621284; PMCID: PMC7361427.
  • Zahedi Niaki O, Anadkat MJ, Chen ST, Fox LP, Harp J, Micheletti RG, Nambudiri VE, Pasieka HB, Shinohara MM, Rosenbach M, et al. Navigating immunosuppression in a pandemic: a guide for the dermatologist from the COVID task force of the medical dermatology society and society of dermatology hospitalists. J Am Acad Dermatol. 2020 Oct;83(4):1150–59. doi:10.1016/j.jaad.2020.06.051. Epub 2020 Jun 19. PMID: 32569797; PMCID: PMC7303642.
  • Loewenstein G, Sunstein CR, Golman R. Disclosure: psychology changes everything. Annu Rev Econ. 2014;6:391–419. Diventa 3. doi:10.1146/annurev-economics-080213-041341.
  • Bavel JJV, Baicker K, Boggio PS, Capraro V, Cichocka A, Cikara M, Crockett MJ, Crum AJ, Douglas KM, Druckman JN, et al. Using social and behavioural science to support COVID-19 pandemic response. Nat Hum Behav. 2020 May;4(5):460–471. doi: 10.1038/s41562-020-0884-z. Epub 2020 Apr 30. PMID: 32355299.
  • Habersaat KB, Betsch C, Danchin M, Sunstein CR, Böhm R, Falk A, Brewer NT, Omer SB, Scherzer M, Sah S, et al. Ten considerations for effectively managing the COVID-19 transition. Nat Hum Behav. 2020 Jul;4(7):677–87. doi:10.1038/s41562-020-0906-x.
  • Toppenberg-Pejcic D, Noyes J, Allen T, Alexander N, Vanderford M, Gamhewage G. Emergency risk communication: lessons learned from a rapid review of recent gray literature on Ebola, Zika, and yellow fever. Health Commun. 2019;34:437–55. doi:10.1080/10410236.2017.1405488.
  • World Health Organization. 2017. Communicating risk in public health emergencies: a WHO guideline for emergency risk communication (ERC) policy and practice. Geneve (Switzerland): World Health Organization. License: CC BY-NC-SA 3.0 IGO.
  • Diotallevi F, Campanati A, Radi G, Martina E, Rizzetto G, Barbadoro P, D’Errico MM, Offidani A. Vaccination against SARS-CoV-2 and psoriasis: the three things every dermatologist should know. J Eur Acad Dermatol Venereol. 2021 Jul;35(7):e428–e430. doi:10.1111/jdv.17256. Epub 2021 Apr 17. PMID: 33780556; PMCID: PMC8251393.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.